European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritis
Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190815005605/en/
“We are excited about the validation of this application which is an important milestone in our ongoing work to improve the lives of people living with rheumatoid arthritis and other inflammatory conditions,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences.
The MAA for filgotinib is supported by 24-week data from the Phase 3 FINCH clinical trials in which once-daily treatment with filgotinib achieved improvements in clinical signs and symptoms, achievement of low disease activity and remission, and inhibition of structural damage for different sub-populations of patients living with RA. Across the FINCH program, safety data were consistent with previously reported results.
“We are very happy with the validation of the filgotinib MAA by the EMA, as this represents the latest step forward in our partnership with Gilead to bring filgotinib as a new treatment option to RA patients across Europe,” said Dr. Walid Abi-Saab, Chief Medical Officer at Galapagos.
The filgotinib filing will be reviewed by the EMA under the centralized licensing procedure for all 28 member states of the European Union, as well as Norway, Iceland and Liechtenstein. In early July, Gilead announced plans to submit a New Drug Application (NDA) for filgotinib for the treatment of RA in the United States before the end of the year.
Filgotinib is an investigational agent and is not approved anywhere globally. Its efficacy and safety have not been established by any regulatory authorities.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world.
Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
About the Galapagos – Gilead Collaboration
Galapagos and Gilead entered into a global collaboration for the development and commercialization of filgotinib in inflammatory indications. The FINCH studies are among several clinical trials of filgotinib in inflammatory diseases, including the EQUATOR Phase 2 study in psoriatic arthritis, the TORTUGA Phase 2 study in ankylosing spondylitis, the DIVERSITY Phase 3 trial in Crohn’s disease (also small bowel and fistulizing Crohn’s disease Phase 2 studies) and the Phase 3 SELECTION trial in ulcerative colitis.
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Its pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Galapagos’ ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.
Gilead Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that EMA, the European Commission and other regulatory agencies may not approve filgotinib for the treatment of RA, and any marketing approvals, if granted, may have significant limitations on its use. As a result, filgotinib may never be successfully commercialized. There is also the possibility that Gilead may be unable to file an NDA for filgotinib in the United States in the currently anticipated timelines. Further, there is the possibility of unfavorable results from ongoing and additional clinical trials involving filgotinib. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
Galapagos Forward-Looking Statements
This release may contain forward-looking statements with respect to Galapagos, including statements regarding Galapagos’ strategic ambitions, the mechanism of action and potential safety and efficacy of filgotinib, the progression and results of clinical studies with filgotinib, the regulatory pathway for filgotinib and the timing of regulatory filings. Galapagos cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Galapagos' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods.
Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs may not support registration or further development of filgotinib due to safety, efficacy or other reasons), Galapagos' reliance on collaborations with third parties (including its collaboration partner for filgotinib, Gilead), and estimating the commercial potential of filgotinib. A further list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities and Exchange Commission (SEC) filings and reports, including in Galapagos' most recent annual report on Form 20-F filed with the SEC and subsequent filings and reports filed by Galapagos with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Sung Lee, Investors
+1 (650) 524-7792
Arran Attridge, Media
+1 (650) 425-8975
Elizabeth Goodwin, Investors
+1 (781) 460-1784
Carmen Vroonen, Media
+32 473 824 874
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons Launches Playond: the Mobile Gaming Service for Everybody15.11.2019 13:30:00 EET | Press release
Bending Spoons, Europe’s number one iOS mobile app developer, has officially launched Playond. This new gaming service gives members unlimited access to an ever-growing catalog of critically acclaimed premium games. The current collection of 60+ games is now available to everybody: Users can play for free with some limitations, or subscribe for an early bird price of $0.99/month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191115005141/en/ (Photo: Bending Spoons) “We are thrilled to have partnered with some of the most dedicated game developers and indie studios in the world. Playond is a service created by mobile gamers, for mobile gamers: our mission is bringing premium games on the App Store to as many players as possible, ultimately leveling-up the mobile gaming experience we can all enjoy" says Mauro Bolis, Project Manager of Playond. In recent years, free-to-play games designed to maximize ad impressions and in-app
Boyaa Poker Tournament Europe 2019. Ticketing Final Countdown15.11.2019 13:18:00 EET | Press release
Boyaa Poker Tournament Europe 2019 will take place from December 5 to 8 at King's Resort with a guaranteed prize of € 200,000. If you want a ticket, hurry up because the final countdown is ticking. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191115005139/en/ (Photo: Business Wire) An Asian experience recommended by European players Boyaa Interactive (Stock code 0434.HK) organized the first BPT in 2015 as a way to enrich its online social poker game and to reach its users worldwide, particularly in Southeast Asia. Now, this BPT comes to Europe for its sixth edition with an interesting proposal that includes a more cheerful and modern image than usual poker tournaments, side events with different buy-ins levels, and flashy trophies for the winners. Some European poker players that participated in previous BPT editions highlighted the diversity of countries that are usually represented in the BPT tournaments, and how the hos
Hagiwara Solutions to Exhibit at SPS 201915.11.2019 12:00:00 EET | Press release
Hagiwara Solutions Co., Ltd. (Elecom group) will exhibit at sps – smart production solution from the 26th to 28th of November 2019, Trade Fair Nuremberg. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191115005082/en/ Introduction Map (Graphic: Hagiwara Solutions) Hagiwara Solutions Co., Ltd. is with Elecom group which is offering solutions with sensing technologies, industrial computers, and SSDs. D-Clue Technologies Co., Ltd. of Elecom group which is good for sensing technologies will join us at sps. SEVEN solutions for your own: Coolant Contamination Detection: How do you manage machine tool coolant for precise products? You can maintain the coolant correctly, using our live sensing system. Let us suggest you make precise products with our coolant contamination detection system. AR Goggle Devices: How do you browse reference documents during your tasks? Workers with our AR goggles don’t need to worry about it. The AR gogg
At CIIE 2019 Panasonic Showcases Solutions to Help Bring to Life China's "Healthy China 2030" Vision15.11.2019 07:22:00 EET | Press release
Panasonic Corporation took part in the 2nd China International Import Expo (CIIE) 2019, which was held in Shanghai from November 5 to 10. Under the theme, "Limitless Care for Healthy Living," Panasonic showcased health and welfare products and solutions that reflect its unique health values. With these products and solutions for a healthy life and aging society, Panasonic aspires to help bring to life China's "Healthy China 2030" vision. Panasonic also introduced its cutting-edge technologies that contribute to the business scene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191114005958/en/ Panasonic booth at CIIE 2019 (Photo: Business Wire) [Video] #CIIE 2019 Panasonic Highlights - The 2nd China International Import Expo https://youtu.be/CbvZClNirQc Panasonic Booth Highlights Solutions for a Healthy Life and an Aging Society 1. "Healthy Environment Unit" With the evolution of sensing and data analytics technology, spaces
Alibaba Group Launches Hong Kong Initial Public Offering15.11.2019 01:47:00 EET | Press release
Alibaba Group Holding Limited (NYSE: BABA) (“Alibaba” or “the Company”) today announced the launch of its Hong Kong public offering (the “Public Retail Offering”), which forms part of the global offering (the “Offering”) of 500,000,000 new ordinary shares (the “Shares”) and listing of its ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “SEHK”) under the stock code “9988.” The Company’s American depositary shares (“ADSs”), each representing eight ordinary shares of the Company, will continue to be listed and traded on the New York Stock Exchange (“NYSE”). Upon listing in Hong Kong, the Hong Kong-listed shares will be fully fungible with the ADSs listed on the NYSE. “Alibaba is guided by our mission to make it easy to do business anywhere with the vision to be a good company that lasts for 102 years. We aim to serve global consumers, of which more than 1 billion will be Chinese consumers, and facilitate more than RMB10 trillion of consumption on our plat
ABI Research Names PTC a Leader in Enterprise Augmented Reality Platforms14.11.2019 22:05:00 EET | Press release
PTC (NASDAQ: PTC) today announced it has been named a leader in the Enterprise Augmented Reality Platforms market for its Vuforia® augmented reality (AR) solution suite in a new research report from ABI Research entitled, “Competitive Assessment – Enterprise Augmented Reality Platforms.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191114005759/en/ ABI Research Names PTC a Leader in Enterprise Augmented Reality Platforms (Graphic: Business Wire) The ABI Research report evaluated vendors on two criteria – innovation and implementation. ABI Research ranked Vuforia first in the innovation category due to PTC’s expansive customer and partner footprint, its advancements in transformative technology and functionality, and the company’s robust digital thread capability. In the implementation category, the ABI Research report highlighted Vuforia’s strength in device support, as well as “options from low-level development tools up
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom